Key Benefits
• Relieves constipation• Increases fecal water content and intestinal transit rate• Shortens defecation time• Reduces colonic mucosal inflammation• Regulates serum constipation-related gastrointestinal peptides• Promotes gut detoxification and fresh breath
Key Data
• Gastric juice survival (pH 3.0, 3h): 99.8 ± 0.10% vs. BB-12 at 95.8 ± 0.50%• Intestinal fluid survival (8h): 73.2 ± 1.3%• HT-29 cell adhesion: 8.9 ± 0.4 bacteria/cell vs. BB-12 at 1.5 ± 0.6• Gut colonization rate at day 7: 25% – benefits maintain for ~1 week• Inhibits E. coli and S. aureus• Utilizes 7 types of oligosaccharides• Total SOD activity: 99.14 ± 9.91 U/mL – demonstrates antioxidant capacity• Constipation relief comparable to BB-12, but superior intestinal transit rate vs. BB-12 and phenolphthalein
Patent
National Invention Patent – A Bifidobacterium longum strain and its application (Patent No.: ZL 201711444295.1)
Commercial Use
Used in multiple products across digestive health, children's probiotics, women's health, metabolic health, oral health, and senior probiotic blends
Why Choose CCFM760?
Superior to industry benchmark BB-12 in both intestinal motility and adhesion – a compelling competitive advantage for B2B buyers
Multi-product validation – already proven across 6+ product categories, demonstrating exceptional formulation stability and broad consumer acceptance
Multi-mechanism action – combines osmotic (water retention), motility (gut hormone regulation), and anti-inflammatory effects for comprehensive constipation relief
Strong intellectual property protection with clear, quantifiable efficacy data – ideal for products targeting gut health, detox, and digestive wellness across all age groups (children, adults, seniors)
